Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + gentamicin is a combination of two antibiotics used together for their synergistic antibacterial effects, particularly against certain resistant bacterial infections. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. Gentamicin is an aminoglycoside antibiotic that binds to the 30S subunit of the bacterial ribosome, inhibiting protein synthesis and causing misreading of mRNA. The combination has been shown in preclinical studies to be more effective than either drug alone against highly penicillin-resistant Streptococcus pneumoniae strains and is considered as a valuable therapeutic alternative for severe infections such as pneumococcal pneumonia[1][2][3]. This regimen may also be used in neonatal sepsis or other serious infections where broad-spectrum coverage including Gram-negative organisms is required[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + gentamicin.